Contraception
Volume 81, Issue 4 , Pages 281-291 , April 2010

Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections

  • Zeev Harel

      Affiliations

    • Division of Adolescent Medicine/Hasbro Children’s Hospital and Department of Pediatrics/Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
    • Corresponding Author InformationCorresponding author. Division of Adolescent Medicine/Hasbro Children's Hospital, Providence, RI 02903, USA.
    • ,
  • Christine Cole Johnson

      Affiliations

    • Department of Biostatistics and Research Epidemiology/Henry Ford Health System, Detroit, MI 48202-3450, USA
    • ,
  • Melanie A. Gold

      Affiliations

    • Division of Student Affairs/University of Pittsburgh Student Health Service and Division of Adolescent Medicine/Department of Pediatrics/University of Pittsburgh, Pittsburgh, PA 15213, USA
    • ,
  • Barbara Cromer

      Affiliations

    • Division of Adolescent Medicine/MetroHealth Medical Center and Department of Pediatrics/Case Western Reserve University School of Medicine, Cleveland, OH 44109-1998, USA
    • ,
  • Edward Peterson

      Affiliations

    • Department of Biostatistics and Research Epidemiology/Henry Ford Health System, Detroit, MI 48202-3450, USA
    • ,
  • Ronald Burkman

      Affiliations

    • Division of General Obstetrics and Gynecology/Department of Obstetrics and Gynecology/Baystate Medical Center, Springfield, MA 01199, USA
    • ,
  • Margaret Stager

      Affiliations

    • Division of Adolescent Medicine/MetroHealth Medical Center and Department of Pediatrics/Case Western Reserve University School of Medicine, Cleveland, OH 44109-1998, USA
    • ,
  • Robert Brown

      Affiliations

    • Department of Pediatrics/Ohio State University College of Medicine, Columbus, OH 43210, USA
    • ,
  • Ann Bruner

      Affiliations

    • Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    • ,
  • Susan Coupey

      Affiliations

    • Division of Adolescent Medicine/Children’s Hospital at Montefiore, and Albert Einstein College of Medicine, New York, NY 10467, USA
    • ,
  • Paige Hertweck

      Affiliations

    • Department of Obstetrics, Gynecology & Women Health/University of Louisville School of Medicine, Louisville, KY 40202, USA
    • ,
  • Henry Bone

      Affiliations

    • Michigan Bone and Mineral Clinic, Detroit, MI 48236, USA
    • ,
  • Kevin Wolter

      Affiliations

    • Pfizer Global Research & Development, New London, CT 06320, USA
    • ,
  • Anita Nelson

      Affiliations

    • Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, CA 90509-2910, USA
    • ,
  • Sharon Marshall

      Affiliations

    • Division of Adolescent Medicine/Children’s Hospital of Michigan and Wayne State University School of Medicine, Detroit, MI 48201, USA
    • ,
  • Laura K. Bachrach

      Affiliations

    • Division of Pediatric Endocrinology/Stanford University School of Medicine, Stanford, CA 94305-5208, USA

Received 3 September 2009 ,Revised 5 November 2009 ,Accepted 9 November 2009.

References 

  1. Darroch JE. Adolescent pregnancy trends and demographics. Curr Womens Health Rep. 2001;1:102–110
  2. Trussell J. Contraceptive efficacy. In:  Hatcher RA,  Trussell J,  Nelson AL,  Cates W,  Stewart FH,  Kowal D editor. Contraceptive technology, 19th revised edition. New York (NY): Ardent Media; 2007;p. 747–826
  3. Mishell DR, Kharma KM, Thorneycroft IH, Nakamura RM. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol. 1972;113:372–376
  4. Riggs BL, Khosla S, Melton J. Sex steroids and the construction and conservation of the adult skeleton. Endocrin Rev. 2002;23:279–302
  5. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab. 1992;75:1060–1065
  6. Bailey DA, McKay HA, Mirwald RL, et al. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res. 1999;14:1672–1679
  7. Baxter-Jones AD, Faulkner RA, Mirwald RL, et al. Bone mineral accrual and age of attainment of adult bone mass: a 15-year longitudinal study from pre-adolescence into adulthood [Abstract, 4th International Conference on Children's Bone Health, Montreal, 2007]. Bone. 2007;40:S25
  8. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434–441
  9. Ott SM. Reproductive hormones and skeletal health in young women. J Clin Endocrinol Metab. 2008;93:1175–1177
  10. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate contraception. BMJ. 1991;303:13–16
  11. Cundy T, Cornish J, Roberts H, et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 1998;92:569–573
  12. Tang OS, Tang G, Yip P, et al. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception. 1999;59:25–29
  13. Scholes D, Lacroix AZ, Ott SM, et al. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93:233–238
  14. Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576–582
  15. Berenson AB, Breitkopf CR, Grady JJ, et al. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004;103:899–906
  16. Merki-Feld G, Neff M, Keller P. A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass. Br J Obstet Gynaecol. 2000;107:863–869
  17. Perrotti M, Bahamondes L, Petta C, Castro S. Forearm bone density in long-term users of oral combined contraception and depot medroxyprogesterone acetate. Fertil Steril. 2001;76:469–473
  18. Walsh JS, Eastell R, Peel NF. Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008;93:1317–1323
  19. Cromer B, Blair J, Mahan J, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatrics. 1996;129:671–676
  20. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. 2003;32:257–259
  21. Lara-Torre E, Edwards CP, Perlman S, Hertweck P. Bone mineral density in adolescent females using DMPA. J Pediatr Adolesc Gynecol. 2004;17:17–21
  22. Cundy T, Cornish J, Evans M, et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994;308:247–248
  23. Petitti D, Piaggio G, Mehta S, et al. Steroid hormone: contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol. 2000;95:736–744
  24. Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–587
  25. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466–1474
  26. Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90–99
  27. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–144
  28. Johnson CC, Burkman RT, Gold MA, et al. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density. Contraception. 2008;77:239–248
  29. Institute of Medicine, Food and Nutrition Board . Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997;
  30. Kaunitz AM, Arias R, McClung MR. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76
  31. Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med. 1991;325:1597–1600
  32. Wang MC, Aguirre M, Bhudhikanok GS, et al. Bone mass and hip axis length in healthy Asian, black, Hispanic, and white American youths. J Bone Miner Res. 1997;12:1922–1935
  33. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122:1142–1152
  34. Orr-Walker BJ, Evans MC, Ames RW, et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf). 1998;49:615–618
  35. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75–87
  36. Scholes D, LaCroix AZ, Ichikawa LE, et al. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception. 2004;69:99–104
  37. Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril. 2008;90:2060–2067
  38. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med. 1997;103:3S–11S
  39. Clark EM, Ness AR, Bishop NJ, et al. Association between bone mass and fracture in children: a prospective cohort study. J Bone Miner Res. 2006;21:1489–1495
  40. Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 1988;81:1804–1809
  41. Sarkar S, Reginster JY, Crans GC, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004;19:394–401
  42. Guilbert ER, Brown JP, Kaunitz AM, et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception. 2009;79:167–177
  43. Http://www.fda.gov/medwatch/SAFETY/2004/DepoProvera_Label.pdf. Accessed January 27, 2005.
  44. Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents — the Black Box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296–301
  45. American College of Obstetricians and Gynecologists . Depot medroxyprogesterone acetate and bone effects. ACOG Committee Opinion No. 415. Obstet Gynecol. 2008;112:727–730

PII: S0010-7824(09)00487-9

doi: 10.1016/j.contraception.2009.11.003

Contraception
Volume 81, Issue 4 , Pages 281-291 , April 2010

Article Tools

* Image Usage & Resolution